Liraglutide
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
Novo Nordisk · Phase 2 · Completed · Enrollment 957
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Sema 0.05 mg | Obesity or overweight | 0.05 mg | n/r | n/r | n/r |
| Sema 0.1 mg | Obesity or overweight | 0.1 mg | n/r | n/r | n/r |
| Sema 0.2 mg | Obesity or overweight | 0.2 mg | n/r | n/r | n/r |
| Sema 0.3 mg | Obesity or overweight | 0.3 mg | n/r | n/r | n/r |
| Sema 0.4 mg | Obesity or overweight | 0.4 mg | n/r | n/r | n/r |
| Sema 0.3 mg (fast dose escalation) | Obesity or overweight | 0.3 mg | n/r | n/r | n/r |
| Sema 0.4 mg (fast dose escalation) | Obesity or overweight | 0.4 mg | n/r | n/r | n/r |
| Lira 3.0 mg | Obesity or overweight | 3.0 mg | n/r | n/r | n/r |
| Placebo Sema 0.05 mg | Obesity or overweight | 0.05 mg | 52 | ITT | n/r |
| Placebo Sema 0.1 mg | Obesity or overweight | 0.1 mg | 52 | ITT | n/r |
| Placebo Sema 0.2 mg | Obesity or overweight | 0.2 mg | 52 | ITT | n/r |
| Placebo Sema 0.3 mg | Obesity or overweight | 0.3 mg | n/r | n/r | n/r |
| Placebo Sema 0.4 mg | Obesity or overweight | 0.4 mg | n/r | n/r | n/r |
| Placebo Sema 0.3 mg (fast dose escalation) | Obesity or overweight | 0.3 mg | 52 | ITT | n/r |
| Placebo Sema 0.4 mg (fast dose escalation) | Obesity or overweight | 0.4 mg | 52 | ITT | n/r |
| Placebo Lira 3.0 mg | Obesity or overweight | 3.0 mg | 52 | ITT | n/r |